Pharma Mar SAU
Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, China, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis, a syntheti… Read more
Pharma Mar SAU (PHMMF) - Net Assets
Latest net assets as of September 2025: $202.24 Million USD
Based on the latest financial reports, Pharma Mar SAU (PHMMF) has net assets worth $202.24 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($342.30 Million) and total liabilities ($140.06 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $202.24 Million |
| % of Total Assets | 59.08% |
| Annual Growth Rate | 1.01% |
| 5-Year Change | 102.84% |
| 10-Year Change | 185.28% |
| Growth Volatility | 269.69 |
Pharma Mar SAU - Net Assets Trend (2002–2024)
This chart illustrates how Pharma Mar SAU's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pharma Mar SAU (2002–2024)
The table below shows the annual net assets of Pharma Mar SAU from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $208.36 Million | +7.71% |
| 2023-12-31 | $193.44 Million | -13.24% |
| 2022-12-31 | $222.96 Million | +25.31% |
| 2021-12-31 | $177.92 Million | +73.20% |
| 2020-12-31 | $102.72 Million | +1277.71% |
| 2019-12-31 | $7.46 Million | -57.33% |
| 2018-12-31 | $17.47 Million | -23.98% |
| 2017-12-31 | $22.98 Million | -52.61% |
| 2016-12-31 | $48.49 Million | -33.60% |
| 2015-12-31 | $73.04 Million | +21.59% |
| 2014-12-31 | $60.07 Million | +21.51% |
| 2013-12-31 | $49.44 Million | +27.65% |
| 2012-12-31 | $38.73 Million | +12.24% |
| 2011-12-31 | $34.50 Million | -1.03% |
| 2010-12-31 | $34.86 Million | -15.26% |
| 2009-12-31 | $41.14 Million | -16.63% |
| 2008-12-31 | $49.34 Million | -50.06% |
| 2007-12-31 | $98.81 Million | -7.80% |
| 2006-12-31 | $107.17 Million | -70.23% |
| 2005-12-31 | $360.04 Million | +19.52% |
| 2004-12-31 | $301.23 Million | +116.28% |
| 2003-12-31 | $139.28 Million | -16.55% |
| 2002-12-31 | $166.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharma Mar SAU's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 22849200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $168.38 Million | 80.81% |
| Common Stock | $10.93 Million | 5.25% |
| Other Comprehensive Income | $16.00K | 0.01% |
| Other Components | $29.03 Million | 13.93% |
| Total Equity | $208.36 Million | 100.00% |
Pharma Mar SAU Competitors by Market Cap
The table below lists competitors of Pharma Mar SAU ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Winmark Corporation
NASDAQ:WINA
|
$1.19 Billion |
|
Ferrotec Corporation
F:FER
|
$1.19 Billion |
|
Huada Automotive Tech Corp Ltd
SHG:603358
|
$1.19 Billion |
|
Port of Tauranga Limited
OTCGREY:PTAUF
|
$1.19 Billion |
|
Guangdong Baolihua New Energy Stock Co LTD
SHE:000690
|
$1.19 Billion |
|
SO.NA.GA.N.R.GDR REGS LN1
F:RZ8G
|
$1.19 Billion |
|
China Southern Power Grid Technology Co Ltd
SHG:688248
|
$1.19 Billion |
|
Hydsoft Technology Co. Ltd. A
SHE:301316
|
$1.19 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharma Mar SAU's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 193,438,000 to 208,359,000, a change of 14,921,000 (7.7%).
- Net income of 26,125,000 contributed positively to equity growth.
- Dividend payments of 11,420,000 reduced retained earnings.
- Share repurchases of 18,696,000 reduced equity.
- New share issuances of 18,911,000 increased equity.
- Other comprehensive income increased equity by 1,001.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $26.12 Million | +12.54% |
| Dividends Paid | $11.42 Million | -5.48% |
| Share Repurchases | $18.70 Million | -8.97% |
| Share Issuances | $18.91 Million | +9.08% |
| Other Comprehensive Income | $1.00K | +0.0% |
| Other Changes | $-1.00 | -0.0% |
| Total Change | $- | 7.71% |
Book Value vs Market Value Analysis
This analysis compares Pharma Mar SAU's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 8.84x to 7.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $9.98 | $88.18 | x |
| 2003-12-31 | $8.33 | $88.18 | x |
| 2004-12-31 | $17.09 | $88.18 | x |
| 2005-12-31 | $21.22 | $88.18 | x |
| 2006-12-31 | $5.54 | $88.18 | x |
| 2007-12-31 | $5.33 | $88.18 | x |
| 2008-12-31 | $2.77 | $88.18 | x |
| 2009-12-31 | $2.25 | $88.18 | x |
| 2010-12-31 | $1.87 | $88.18 | x |
| 2011-12-31 | $2.14 | $88.18 | x |
| 2012-12-31 | $2.29 | $88.18 | x |
| 2013-12-31 | $2.89 | $88.18 | x |
| 2014-12-31 | $3.47 | $88.18 | x |
| 2015-12-31 | $4.17 | $88.18 | x |
| 2016-12-31 | $2.84 | $88.18 | x |
| 2017-12-31 | $1.46 | $88.18 | x |
| 2018-12-31 | $1.16 | $88.18 | x |
| 2019-12-31 | $0.62 | $88.18 | x |
| 2020-12-31 | $5.61 | $88.18 | x |
| 2021-12-31 | $9.84 | $88.18 | x |
| 2022-12-31 | $12.34 | $88.18 | x |
| 2023-12-31 | $10.80 | $88.18 | x |
| 2024-12-31 | $11.86 | $88.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharma Mar SAU utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.54%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.94%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 1.68x
- Recent ROE (12.54%) is above the historical average (-13.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | -21.12% | -53.52% | 0.24x | 1.63x | $-51.95 Million |
| 2003 | -18.83% | -32.64% | 0.29x | 1.98x | $-40.15 Million |
| 2004 | 0.45% | 204.63% | 0.00x | 1.12x | $-28.75 Million |
| 2005 | 0.01% | 8.92% | 0.00x | 1.09x | $-35.96 Million |
| 2006 | -49.39% | -63.81% | 0.34x | 2.28x | $-58.50 Million |
| 2007 | -52.93% | -59.29% | 0.37x | 2.43x | $-60.24 Million |
| 2008 | -88.64% | -41.55% | 0.51x | 4.21x | $-48.67 Million |
| 2009 | -68.40% | -22.80% | 0.58x | 5.14x | $-32.25 Million |
| 2010 | -35.73% | -8.03% | 0.67x | 6.69x | $-15.78 Million |
| 2011 | -3.47% | -0.90% | 0.70x | 5.51x | $-5.33 Million |
| 2012 | 15.58% | 4.77% | 0.69x | 4.72x | $2.36 Million |
| 2013 | 21.27% | 8.06% | 0.74x | 3.56x | $6.00 Million |
| 2014 | 20.53% | 8.82% | 0.74x | 3.15x | $6.73 Million |
| 2015 | 8.57% | 3.42% | 0.91x | 2.76x | $-1.10 Million |
| 2016 | -45.99% | -13.31% | 0.82x | 4.22x | $-29.32 Million |
| 2017 | -99.55% | -14.91% | 0.96x | 6.99x | $-29.43 Million |
| 2018 | -25.90% | -3.41% | 1.03x | 7.38x | $-7.67 Million |
| 2019 | -80.71% | -10.70% | 0.69x | 10.96x | $-10.32 Million |
| 2020 | 133.62% | 50.85% | 0.82x | 3.22x | $126.99 Million |
| 2021 | 52.19% | 40.40% | 0.62x | 2.07x | $75.07 Million |
| 2022 | 22.14% | 25.14% | 0.50x | 1.76x | $27.06 Million |
| 2023 | 0.59% | 0.72% | 0.46x | 1.76x | $-18.21 Million |
| 2024 | 12.54% | 14.94% | 0.50x | 1.68x | $5.29 Million |
Industry Comparison
This section compares Pharma Mar SAU's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharma Mar SAU (PHMMF) | $202.24 Million | -21.12% | 0.69x | $1.19 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |